Affiliations: Department of Thoracic, Cardiac and Vascular Surgery, Clinical Research Laboratory, University Hospital Tuebingen, Germany
Correspondence:
[*]
Corresponding author: Dr. rer. nat. Stefanie Krajewski, Department of Thoracic and Cardiovascular Surgery, University Hospital Tuebingen, Calwerstr. 7, 72076 Tuebingen, Germany. Tel.: +49 7071 29 83303; Fax: +49 7071 29 5369; E-mail: stefanie.krajewski@uni-tuebingen.de.
Abstract: Background:Chitosan is used in a wide field of applications and therapies and has been reported to be an effective hemostyptic. The objective of this study was to provide further information about the use of chitosan as a hemostyptic agent also taking into focus its hemocompatible effects. Methods:Human whole blood (n=5) was anticoagulated with heparin, treated with different chitosan concentrations (0, 2.5, 5, 7.5, 10, 12.5, 25 mg/mL) and incubated at 37°C for 30 minutes. Before and after incubation different parameters for coagulation and hemocompatibility were evaluated. Results:Blood treated with high chitosan concentrations showed enhanced coagulation, which we evaluated with activated clotting time, activated partial thromboplastin time and concentration of thrombin–antithrombin complexes. Furthermore, we observed an activation of blood platelets, complement cascade and granulocytes in the groups treated with chitosan. Conclusion:Our data indicate that chitosan activates human blood coagulation and hence has good properties as a hemostyptic agent. However, inflammatory parameters were upregulated after direct contact with human blood indicating that systemic administration of chitosans should not be performed whereas the topical use of chitosan as a hemostypticum should not present any hazard with regard to adverse inflammatory reactions at the site of application.
Keywords: Chitosan, hemostypticum, coagulation, hemocompatibility, platelets, complement system
